Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Anti-interleukin-2 Receptor Antibodies—basiliximab and Daclizumab—for the Prevention of Acute Rejection in Renal Transplantation

The use of antibody induction after kidney transplantation has increased from 25% to 63% in the past decade and roughly one half of the induction agent used is anti-interleukin-2 receptor antibody (IL-2RA, ie, basiliximab or daclizumab). When combined with calcineurin inhibitor (CNI)-based immunosuppression, IL-2RAs have been shown to reduce the incidence of acute rejection, one of the predictors of poor graft survival, without increasing risks of infections and malignancies in kidney transplantation. For low-immunological-risk patients, IL-2RAs, as compared with lymphocyte-depleting antibodies, are equally efficacious and have better safety profiles. For high-risk patients, however, IL-2RAs may be inferior to lymphocyte-depleting antibodies for the prophylaxis of acute rejection. In an effort to reduce toxicities of other immunosuppressive medications without increasing the risk of acute rejection and chronic graft loss, IL-2RAs have often been combined with steroid- and CNI-sparing immunosuppression protocols. More data support the benefits of early steroid withdrawal with IL-2RA in low-risk patients, but preferred induction therapy for high-risk patients has yet to be determined. Although CNI-sparing protocols with IL-2RA may preserve renal function and improve long-term survival in selected patients, further studies are needed to identify those who benefit most from this strategy.

[1]  A. Webster,et al.  Steroid avoidance or withdrawal for kidney transplant recipients. , 2016, The Cochrane database of systematic reviews.

[2]  E. Woodle,et al.  A Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial Comparing Early (7 Day) Corticosteroid Cessation Versus Long-Term, Low-Dose Corticosteroid Therapy , 2008, Annals of surgery.

[3]  J. Gaynor,et al.  Randomized Trial of Mycophenolate Mofetil Versus Enteric-Coated Mycophenolate Sodium in Primary Renal Transplant Recipients Given Tacrolimus and Daclizumab/Thymoglobulin: One Year Follow-Up , 2008, Transplantation.

[4]  W. Meyers,et al.  Long‐Term Outcome of Early Steroid Withdrawal After Kidney Transplantation in African American Recipients Monitored by Surveillance Biopsy , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  F. Schena,et al.  A Randomized, Multicenter Study of Steroid Avoidance, Early Steroid Withdrawal or Standard Steroid Therapy in Kidney Transplant Recipients , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  P. Halloran,et al.  Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.

[7]  J. Gaynor,et al.  A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow‐up , 2007, Clinical transplantation.

[8]  M. Salvadori,et al.  A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  K. Salmela,et al.  Single Bolus Antithymocyte Globulin Versus Basiliximab Induction in Kidney Transplantation With Cyclosporine Triple Immunosuppression: Efficacy and Safety , 2007, Transplantation.

[10]  L. Rostaing,et al.  Renal function with delayed or immediate cyclosporine microemulsion in combination with enteric‐coated mycophenolate sodium and steroids: results of follow up to 30 months post‐transplant , 2007, Clinical transplantation.

[11]  A. Novick,et al.  Kidney Transplantation With Sirolimus and Mycophenolate Mofetil–Based Immunosuppression: 5-Year Results of a Randomized Prospective Trial Compared to Calcineurin Inhibitor Drugs , 2007, Transplantation.

[12]  A. Novick,et al.  Kidney Transplantation With Sirolimus and Mycophenolate Mofetil–Based Immunosuppression: 5-Year Results of a Randomized Prospective Trial Compared to Calcineurin Inhibitor Drugs , 2007 .

[13]  B. Nashan,et al.  Cyclosporine Sparing with Mycophenolate Mofetil, Daclizumab and Corticosteroids in Renal Allograft Recipients: The CAESAR Study , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  J. Pascual,et al.  12‐month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients , 2007, Transplant international : official journal of the European Society for Organ Transplantation.

[15]  D. Brennan,et al.  Rabbit antithymocyte globulin versus basiliximab in renal transplantation. , 2006, The New England journal of medicine.

[16]  B. Dimitrov,et al.  Long‐Term Renal Allograft Function on a Tacrolimus‐Based, Pred‐Free Maintenance Immunosuppression Comparing Sirolimus vs. MMF † , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  Minzhuan Lin,et al.  Two‐dose basiliximab compared with two‐dose daclizumab in renal transplantation: a clinical study , 2006, Clinical transplantation.

[18]  L. Rostaing,et al.  Impact of Early or Delayed Cyclosporine on Delayed Graft Function in Renal Transplant Recipients: A Randomized, Multicenter Study , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  M. Moritz,et al.  Safety and Efficacy of Steroid Withdrawal Two Days after Kidney Transplantation: Analysis of Results at Three Years , 2006, Transplantation.

[20]  J. Squifflet,et al.  Two Corticosteroid-Free Regimens—Tacrolimus Monotherapy after Basiliximab Administration and Tacrolimus/Mycophenolate Mofetil—in Comparison with a Standard Triple Regimen in Renal Transplantation: Results of the Atlas Study , 2005, Transplantation.

[21]  V. Dharnidharka.  Costimulation blockade with belatacept in renal transplantation. , 2005, The New England journal of medicine.

[22]  D. Axelrod,et al.  Alemtuzumab Induction and Prednisone‐Free Maintenance Immunotherapy in Kidney Transplantation: Comparison with Basiliximab Induction—Long‐Term Results , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[23]  M. Moritz,et al.  Comparison of Steroid Avoidance in Tacrolimus/Mycophenolate Mofetil and Tacrolimus/Sirolimus Combination in Kidney Transplantation Monitored by Surveillance Biopsy , 2005, Transplantation.

[24]  J. Gaynor,et al.  A Randomized Trial of Three Renal Transplant Induction Antibodies: Early Comparison of Tacrolimus, Mycophenolate Mofetil, and Steroid Dosing, and Newer Immune-Monitoring1 , 2005, Transplantation.

[25]  M. Moritz,et al.  Avoidance of Chronic Steroid Therapy in African American Kidney Transplant Recipients Monitored by Surveillance Biopsy: 1‐Year Results , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  K. Budde,et al.  Corticosteroid-Free Immunosuppression with Tacrolimus, Mycophenolate Mofetil, and Daclizumab Induction in Renal Transplantation , 2005, Transplantation.

[27]  J. Alexander,et al.  A prospective, pilot study of early corticosteroid cessation in high-immunologic-risk patients: the Cincinnati experience. , 2005, Transplantation proceedings.

[28]  C. Watson,et al.  Multicenter, Randomized Study of the Effectiveness of Basiliximab in Avoiding Addition of Steroids to Cyclosporine A Monotherapy in Renal Transplant Recipients , 2005, Transplantation.

[29]  H. Gritsch,et al.  A Multicenter Pilot Study of Early (4‐Day) Steroid Cessation in Renal Transplant Recipients Under Simulect, Tacrolimus and Sirolimus , 2005, American Journal of Transplantation.

[30]  L. Truong,et al.  A Truncated-Dose Regimen of Daclizumab for Prevention of Acute Rejection in Kidney Transplant Recipients: A Single-Center Experience , 2004, Transplantation.

[31]  J. Pascual,et al.  Steroid Withdrawal in Renal Transplant Patients on Triple Therapy with a Calcineurin Inhibitor and Mycophenolate Mofetil: A Meta-analysis of Randomized, Controlled Trials , 2004, Transplantation.

[32]  C. Ponticelli,et al.  Everolimus and Reduced-Exposure Cyclosporine in de novo Renal-Transplant Recipients: A Three-Year Phase II, Randomized, Multicenter, Open-Label Study , 2004, Transplantation.

[33]  S. Head,et al.  De Novo Kidney Transplantation Without Use of Calcineurin Inhibitors Preserves Renal Structure and Function at Two Years , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[34]  L. Rostaing,et al.  Sequential Protocols using Basiliximab versus Anti-Thymocyte Globulins in Renal-Transplant Patients Receiving Mycophenolate Mofetil and Steroids , 2004, Transplantation.

[35]  J. Chapman,et al.  Calcineurin Inhibitor Nephrotoxicity: Longitudinal Assessment by Protocol Histology , 2004, Transplantation.

[36]  R. Stratta,et al.  One-year outcomes in simultaneous kidney-pancreas transplant recipients receiving an alternative dosing regimen of daclizumab. , 2004, Transplantation proceedings.

[37]  G. Borm,et al.  Steroid‐Withdrawal at 3 Days After Renal Transplantation with Anti‐IL‐2 Receptor α Therapy: A Prospective, Randomized, Multicenter Study , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[38]  Julio Pascual,et al.  Everolimus with Optimized Cyclosporine Dosing in Renal Transplant Recipients: 6‐Month Safety and Efficacy Results of Two Randomized Studies , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[39]  G. Ciancio,et al.  The use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants , 2003, Clinical transplantation.

[40]  O. Pankewycz,et al.  Basiliximab plus low‐dose cyclosporin vs. OKT3 for induction immunosuppression following renal transplantation , 2003, Clinical transplantation.

[41]  G. Ciancio,et al.  The Use of Daclizumab, Tacrolimus and Mycophenolate Mofetil in African‐American and Hispanic First Renal Transplant Recipients , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[42]  W. Almawi,et al.  Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation. , 2003, Molecular immunology.

[43]  D. Adu,et al.  Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials , 2003, BMJ : British Medical Journal.

[44]  P. Bacchetti,et al.  Sirolimus Prolongs Recovery from Delayed Graft Function After Cadaveric Renal Transplantation , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[45]  G. Ciancio,et al.  Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression. , 2003, Transplantation proceedings.

[46]  A. Monaco,et al.  Multicenter Randomized Prospective Trial of Steroid Withdrawal in Renal Transplant Recipients Receiving Basiliximab, Cyclosporine Microemulsion and Mycophenolate Mofetil , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[47]  L. Rostaing,et al.  Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. , 2003, Transplantation.

[48]  F. Vincenti,et al.  Pharmacokinetic and Pharmacodynamic Studies of One or Two Doses of Daclizumab in Renal Transplantation , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[49]  J. Kovarik,et al.  A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations1 , 2002, Transplantation.

[50]  E. Benedetti,et al.  Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients. , 2002, Transplantation proceedings.

[51]  G. Ciancio,et al.  Effect of daclizumab, tacrolimus and mycophenolate mofetil in racial minority first renal transplant recipients. , 2002, Transplantation proceedings.

[52]  G. Ciancio,et al.  Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients1 , 2002, Transplantation.

[53]  O. Toupance,et al.  Immunoprophylaxis with Basiliximab Compared with Antithymocyte Globulin in Renal Transplant Patients Receiving MMF‐containing Triple Therapy , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[54]  F. Citterio.  Steroid side effects and their impact on transplantation outcome. , 2001, Transplantation.

[55]  M. Pescovitz,et al.  BASILIXIMAB VERSUS ANTITHYMOCYTE GLOBULIN FOR PREVENTION OF ACUTE RENAL ALLOGRAFT REJECTION1,2 , 2001, Transplantation.

[56]  A. Hoitsma,et al.  Two doses of daclizumab are sufficient for prolonged interleukin-2Ralpha chain blockade. , 2001, Transplantation.

[57]  H. Theodoropoulou,et al.  Monoclonal antibody basiliximab with low cyclosporine dose as initial immunosuppression. , 2001, Transplantation proceedings.

[58]  R. Lechler,et al.  A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. , 2001, Transplantation.

[59]  M. Pescovitz,et al.  Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. , 2001, Transplantation.

[60]  B. Kiberd,et al.  A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. , 2001, Transplantation.

[61]  K. Johny,et al.  Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients. , 2001 .

[62]  B. Nashan,et al.  MULTICENTER TRIAL EXPLORING CALCINEURIN INHIBITORS AVOIDANCE IN RENAL TRANSPLANTATION , 2001, Transplantation.

[63]  Johnny C. Hong,et al.  A CALCINEURIN ANTAGONIST-FREE INDUCTION STRATEGY FOR IMMUNOSUPPRESSION IN CADAVERIC KIDNEY TRANSPLANT RECIPIENTS AT RISK FOR DELAYED GRAFT FUNCTION1 , 2001, Transplantation.

[64]  J. Kovarik,et al.  Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients , 2001, Clinical transplantation.

[65]  O. Pankewycz,et al.  Induction strategy using basiliximab combined with mycophenolate MMF and immediate low-dose cyclosporin is steroid sparing and more effective than OKT3. , 2001, Transplantation proceedings.

[66]  G. Iaria,et al.  Preliminary results of a prospective randomized study of basiliximab in kidney transplantation. , 2001, Transplantation proceedings.

[67]  A. Miller,et al.  Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression. , 2001, Transplantation proceedings.

[68]  J. Roberts,et al.  A calcineurin inhibitor‐sparing regimen with sirolimus, mycophenolate mofetil, and anti‐CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function , 2000, Clinical transplantation.

[69]  F. Oppenheimer,et al.  Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. , 2000, Transplantation.

[70]  L. Pape,et al.  Interleukin-2 receptor antibodyinduced alterations of ciclosporin dose requirements in paediatric transplant recipients , 2000, The Lancet.

[71]  H. Auchincloss,et al.  Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. , 2000, Journal of the American Society of Nephrology : JASN.

[72]  S. Mulgaonkar,et al.  The effect of Daclizumab in a high‐risk renal transplant population , 2000, Clinical transplantation.

[73]  F. Wright,et al.  Daclizumab in live donor renal transplantation. , 2000, Transplantation proceedings.

[74]  S. Mulgaonkar,et al.  Efficacy of Daclizumab in an African-American and Hispanic renal transplant population , 2000, Transplant International.

[75]  F. Vincenti,et al.  Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis , 2000, Transplant international : official journal of the European Society for Organ Transplantation.

[76]  D. Stablein,et al.  Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group. , 1999, Transplantation.

[77]  G. Becker,et al.  Impact of acute rejection therapy on infections and malignancies in renal transplant recipients. , 1999, Transplantation.

[78]  F. Vincenti.  Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation. , 1999, Transplantation proceedings.

[79]  M. Hall,et al.  Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. , 1999, Transplantation.

[80]  B. Nashan,et al.  Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. , 1999, Transplantation.

[81]  J. Thistlethwaite,et al.  Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group. , 1998, Transplantation.

[82]  J. Kovarik,et al.  Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. , 1997, Transplantation.

[83]  J. Soulillou,et al.  Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients , 1997, The Lancet.

[84]  D. Mould,et al.  A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. , 1997, Transplantation.

[85]  M. Schreier,et al.  Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. , 1995, Transplantation.

[86]  W. Payne,et al.  THE IMPACT OF AN ACUTE REJECTION EPISODE ON LONG‐TERM RENAL ALLOGRAFT SURVIVAL (t1/2)1,2 , 1994, Transplantation.

[87]  D. Dunn,et al.  Risk factors for chronic rejection in renal allograft recipients. , 1993, Transplantation.

[88]  T. Waldmann,et al.  A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. , 1991, Transplantation.

[89]  P. Friend,et al.  DELAYED ALLOGRAFT REJECTION IN PRIMATES TREATED WITH ANTI‐IL-2 RECEPTOR MONOCLONAL ANTIBODY CAMPATH‐6 , 1988, Transplantation.

[90]  R. Marcén,et al.  A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function , 2009, Clinical transplantation.

[91]  Joan W. Miller,et al.  Long-Term Results of Rabbit Antithymocyte Globulin and Basiliximab Induction , 2008 .

[92]  D. Leehey,et al.  Improved graft survival after renal transplantation in the United States, 1988 to 1996. , 2000, The New England journal of medicine.

[93]  J. Kovarik,et al.  Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. , 1999, Transplantation.

[94]  J Neylan,et al.  Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. , 1998, The New England journal of medicine.

[95]  N. Sinclair,et al.  Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[96]  T. Waldmann,et al.  Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody. , 1989, Transplantation.